Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel vs Solvent-based Taxanes in Advanced Ovarian Cancer
NCT05737303Phase 3Recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in epithelial ovarian carcinoma (EOC), fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoint: Progression Free Survival at 20 months. Started Nov 2023; status: recruiting.
02
Drugs
paclitaxel
03
Conditions
epithelial ovarian carcinoma (EOC)fallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT05737303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05737303.